Skip to main content

Table 1 Baseline clinical characteristics of study subjects

From: Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding

Variables Conventional therapy (n = 112) UI-EWD therapy (n = 55) P-value
Age (year)§ 74 (39–88) 64 (25–89) 0.181
Sex (male)§ 66 (58.9) 32 (58.2) 0.875
Medication, n (%)
Anticoagulant 9 (8.0) 3 (5.5) 0.753+
Antiplatelet agent 32 (28.6) 9 (16.4) 0.085
Anticoagulant and antiplatelet agent 11 (9.8) 5 (9.1) 0.549+
White blood cell (1000/μL) § 6580 (2100–20,570) 7270 (2290–36,410) 0.337
Hb (g/dL)§ 10.0 (12.0–4.9) 12.4 (6.4–16.0) 0.369
Platelet count (1000/μL)§ 208 (55–654) 222 (49–371) 0.550
PTs (INR)§ 1.03 (0.84–5.18) 1.05 (0.84–18.40) 0.320
aPTT (s)§ 36.5 (24.2–79.2) 36.3 (26.2–79.2) 0.457
BUN (mg/dL)§ 16.4 (5.5–139.8) 15.5 (6.5–95.3) 0.372
Cr (mg/dL)§ 0.87 (0.29–8.43) 0.83 (0.29–7.28) 0.502
CCI ≥ 6, n (%) 46 (41.4) 39 (70.9) 0.048
Follow-up duration (day)§ 131 (7–668) 47 (7–797) 0.674
  1. UGI, Upper gastrointestinal; LGI, Lower gastrointestinal; Hb, Hemoglobin; PTs, Prothrombin time; aPTT, Activated partial thromboplastin time; BUN, Blood urea nitrogen; Cr, Creatinine; CCI, Charlson Comorbidity index
  2. §Median (range)
  3. +Fisher’s exact test
  4. *P-values were calculated using the t-test or Fisher calculated using the of the conventional therapy group and the UI-EWD therapy group